Thursday, September 25, 2014 12:17:23 PM
I will be gone
To day i received this maybe it can help hold on for the good days to come.
See you next year.
Thank you for your e-mail and your continued interest in Natcore.
As you probably know, we were very encouraged by the results of the testing in China and we are in the process of negotiating a joint development agreement with the Chinese manufacturer we have been working with. I hesitate to set time lines but I think we will have a joint agreement with them later this year or in early 2014.
We hope to have a better product available for the Chinese because of the work we are doing with Fraunhofer ISE, the independent laboratory in Germany, but we are aggressively working on agreements and will not let that interrupt the negotiations.
I spent over 30 years working at reasonably large Wall Street brokerage firms and although there are many things I do not know, the one thing I think I do know is that it is impossible to explain market fluctuations especially with small cap stocks. There is nothing in our operations or business model that has changed or would cause this weakness. As I mentioned above, we are having great successes with our Black Silicon progress in China as well as with Fraunhofer ISE. Our laser applications are also moving faster than expected. I mention these two applications since Black Silicon and the back-side laser contact applications are the closest to commercialization. They are not necessarily the most significant of our patents, but being business people, we are always focus on generating revenue sooner rather than later. We also feel we will receive some revenue from our best-of-breed consulting service.
One potential reason for the weakness may be that the restriction placed on free trading shares from our last capital raise was lifted at the end of August. I suspect several of the participants in that capital raise have been taking profits since they had to hold the stock for one year.
We truly understand your concerns. We will keep you updated on our progress.
Best regards,
Thomas J. Scarpa
Sr. Vice President
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM